Reverse Genetics Is Best Path To Cell Culture Vaccines – FDA Committee
Executive Summary
Reverse genetics holds the greatest promise for developing cell culture-based vaccines, FDA's Vaccines & Related Biological Products Advisory Committee said Feb. 19
You may also be interested in...
Influenza B strain confirmed
FDA's Vaccines & Related Biological Products Advisory Committee unanimously confirms its selection of Yamagata lineage Shanghai/361/2002-like influenza B strain for 2004-2005 vaccine by teleconference March 17. In February, the committee said the two influenza A strains in next season's flu vaccine should be a New Caledonia/20/1999 (H1N1)-like strain and a Fujian/411/2002 (H3N2)-like strain, but delayed a final decision on influenza B (1"The Pink Sheet" Feb. 23, 2004, p. 32)...
Influenza B strain confirmed
FDA's Vaccines & Related Biological Products Advisory Committee unanimously confirms its selection of Yamagata lineage Shanghai/361/2002-like influenza B strain for 2004-2005 vaccine by teleconference March 17. In February, the committee said the two influenza A strains in next season's flu vaccine should be a New Caledonia/20/1999 (H1N1)-like strain and a Fujian/411/2002 (H3N2)-like strain, but delayed a final decision on influenza B (1"The Pink Sheet" Feb. 23, 2004, p. 32)...
Influenza vaccine formulation
FDA's Vaccines & Related Biological Products Advisory Committee will meet March 17 by teleconference to finalize the influenza vaccine formulation for the 2004-2005 flu season. At a Feb. 18-19 meeting, the committee recommended switching one of the two influenza A strains, and switching a Victoria lineage strain to Yamagata for the influenza B component (1"The Pink Sheet" Feb. 23, 2004, p. 32). A speakerphone will be available to the public in FDA's Building 29 B Conference Room C from 1 p.m. to 5 p.m...